Recent Investment Analysts’ Ratings Changes for SCYNEXIS (SCYX)

A number of research firms have changed their ratings and price targets for SCYNEXIS (NASDAQ: SCYX):

  • 1/9/2020 – SCYNEXIS had its “buy” rating reaffirmed by analysts at LADENBURG THALM/SH SH. They now have a $6.00 price target on the stock.
  • 1/8/2020 – SCYNEXIS was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 1/8/2020 – SCYNEXIS was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.00 price target on the stock. According to Zacks, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. “
  • 12/20/2019 – SCYNEXIS was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. “
  • 12/16/2019 – SCYNEXIS had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.50 price target on the stock.
  • 12/13/2019 – SCYNEXIS was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. “
  • 12/4/2019 – SCYNEXIS was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

SCYX stock opened at $1.05 on Thursday. SCYNEXIS Inc has a 1-year low of $0.66 and a 1-year high of $1.90. The firm has a market cap of $52.53 million, a P/E ratio of -2.14 and a beta of 2.16. The business’s 50 day moving average is $0.92 and its 200-day moving average is $1.09. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 2.60.

SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. SCYNEXIS had a negative return on equity of 230.55% and a negative net margin of 11,653.81%. Sell-side analysts forecast that SCYNEXIS Inc will post -0.44 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning grew its position in SCYNEXIS by 11.3% during the 3rd quarter. Creative Planning now owns 154,700 shares of the company’s stock worth $165,000 after acquiring an additional 15,700 shares during the last quarter. BlackRock Inc. lifted its stake in shares of SCYNEXIS by 152.0% in the 2nd quarter. BlackRock Inc. now owns 854,880 shares of the company’s stock valued at $1,121,000 after purchasing an additional 515,707 shares during the period. Virtu Financial LLC acquired a new position in shares of SCYNEXIS in the 3rd quarter valued at $97,000. Vanguard Group Inc. increased its position in shares of SCYNEXIS by 47.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,373,737 shares of the company’s stock valued at $3,110,000 after buying an additional 766,865 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of SCYNEXIS in the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 32.00% of the company’s stock.

SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.

Featured Article: Initial Coin Offering (ICO)

Receive News & Ratings for SCYNEXIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.